11 Quotes by Robert Hazlett

Pfizer is clearly a winner here. Pfizer is clearly putting their solid foot forward. They've got a good franchise and it's good potential for the next couple years.

We had heard some investors were expecting a much worse forecast for next year, and those fears have been allayed.

We knew 2003 was going to be a challenge, but it appears it's going to be more of a challenge than we expected.

Every drug is a balance of benefits and risks, ... With any drug there are risks and you have to be careful with all these drugs in terms of liver damage. No drug is perfect. They're not lollipops.

The scale of the deal speaks volumes. This is a seminal event in the life of the company.

It's at the margin. It's $3 billion and change of a $50 billion company, so it's not inconsequential, but is it critical to the growth of the company going forward? No.

For investors in Pfizer, this is a meaningful event. This risk has been a significant overhang for some time.

It's not very confidence inspiring to pull your guidance, and because of that we're looking hard at our 2006 estimates.

The big drug companies are under duress on almost every front. There are challenges everywhere from generics, from the FDA, from managed care and from self-appointed public watchdogs criticizing the industry, and with attacks on direct-to-consumer advertising,